Safety and Efficacy of Topical Use of Imiquimod (Beselna Cream 5％) for the Treatment of Actinic Keratosis : A Retrospective Multicenter Collaborative Clinical Study

DOI Web Site Web Site 4 References
  • YASUDA Masahito
    Department of Dermatology, Gunma University Graduate School of Medicine
  • OKADA Etsuko
    Department of Dermatology, National Hospital Organization Takasaki General Medical Center
  • HASEGAWA, Michiko
    Department of Dermatology, Isesaki Municipal Hospital
  • ENDO Yukie
    Department of Dermatology, Tone Central Hospital
  • RYUZAKI Keiichiro
    Department of Dermatology, National Hospital Organization Takasaki General Medical Center
  • OKADA Katsuyuki
    Department of Dermatology, Kiryu Kosei General Hospital
  • TAMURA Atsushi
    Department of Dermatology, Isesaki Municipal Hospital
  • ISHIKAWA Osamu
    Department of Dermatology, Gunma University Graduate School of Medicine

Bibliographic Information

Other Title
  • 日光角化症に対するイミキモド（ベセルナクリーム 5％）外用の有効性， 安全性を評価する後ろ向き多施設共同臨床研究
  • 治療 日光角化症に対するイミキモド(ベセルナクリーム5%)外用の有効性,安全性を評価する後ろ向き多施設共同臨床研究
  • チリョウ ニッコウ カッカショウ ニ タイスル イミキモド(ベセルナクリーム 5%)ガイヨウ ノ ユウコウセイ,アンゼンセイ オ ヒョウカ スル ウシロ ムキ タシセツ キョウドウ リンショウ ケンキュウ

Search this article

Description

<p>Actinic keratosis is an intraepidermal carcinoma induced by DNA damage in epidermal cells caused by exposure to ultraviolet radiation.Recently,the incidence of actinic keratosis has increased among the aging population, and thus, early detection and treatment is important.In2011, imiquimod (Beselna Cream 5%) was approved for the additional indication of actinic keratosis.Weconducted a retrospective multicenter collaborative clinical study between June 2012 and June 2013 to examine the safety and efficacy of topical use of imiquimod in patients with actinic keratosis.Inthis study, 46 patients (mean age, 82.2 years; 23 men, 23 women) were included.Themean disease duration was 29.3 months.Ninepatients had a history of treatment for actinic keratosis.Beselna Cream 5％ was used according to the instructions in its package insert.One treatment cycle included external application 3 times a week for 4 weeks and discontinuation of its use for 4 weeks.Thecycle was repeated once when the efficacy was insufficient.The response rate was 78％.Eighteen patients were successfully followed up until 12 months after the end of the treatment, and no recurrence was observed in any of the patients.The adverse event of the topical use of imiquimod was local skin reaction, with an incidence of 47.8％ and 8.7％ in cycle 1 and cycle 2,respectively.Withdrawal of imiquimod treatment was required in 1 patient ; however, the symptoms were immediately relieved after the discontinuation of imiquimod treatment.Consistentwith the previous findings, our findings indicate that topical use of imiquimod is highly effective and is associated with a low recurrence rate of actinic keratosis ; therefore, we believe that imiquimod can be used as a first-line drug for the treatment of actinic keratosis.</p>

Journal

References(4)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top